Expected Results In Vitro GH Release Ipamorelin is expected to stimulate the release of GH from cultured cells in a dose-dependent manner

GHRP-6 in Cytoprotection and Tissue Repair GHRP-6's research literature extends significantly beyond GH release into tissue protection and repair : Stroke therapy: A Phase I/II clinical trial examined GHRP-6 combined with recombinant EGF for acute ischemic stroke one of the few GHS compounds to reach clinical trials for a non-endocrine indication (Berlanga-Acosta et al., 2024) Lung injury: GHRP-6 ameliorates acute lung injury and prevents its progression to interstitial fibrosis in preclinical models (GHRP-6 in lung injury, 2025) Organ failure prevention: GHRP-6 has been investigated for multiple organ failure prevention in critical illness (Berlanga-Acosta et al., 2006) Cardiac protection: The peptide protects against doxorubicin-induced cardiotoxicity through prosurvival pathway activation (GHRP-6 cardioprotection, 2024) These cytoprotective effects appear to involve GHSR-1a-mediated anti-inflammatory, anti-apoptotic, and antioxidant signaling potentially independent of GH release itself

A side effect seen with older secretagogues like GHRP-6
To view or add a comment, sign in Tirzepatide is a dual GIP and GLP-1 receptor agonist designed for research use , offering a unique approach to studying glucose regulation and metabolic health
5 CR reduces fasting insulin levels and improves insulin sensitivity in overweight individuals, whereby these effects may be more pronounced with regular IF compared with chronic CR